Karahan Salih, Afsar Baris, Kanbay Mehmet
Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Department of Medicine, Division of Nephrology, Suleyman Demirel University School of Medicine, Isparta, Turkey.
Clin Kidney J. 2018 Aug;11(4):530-531. doi: 10.1093/ckj/sfy044. Epub 2018 Jun 26.
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels.
不对称二甲基精氨酸（ADMA）是一种内源性一氧化氮合酶抑制剂，与慢性肾脏病（CKD）患者的内皮功能受损及不良预后相关。此外，氧化应激和炎症也是CKD患者的常见问题，二者在CKD患者动脉粥样硬化的发生发展及心血管事件增加方面均起重要作用。维生素C可能是一种有前景的药物，可通过降低氧化应激和ADMA水平来改善CKD患者的预后。
